Defense Department sees results on outcomes research

Traynor, Kate
April 2010
American Journal of Health-System Pharmacy;4/15/2010, Vol. 67 Issue 8, p590
Academic Journal
The article presents information on the U.S. Department of Defense's Pharmacy Outcomes Research Team, or PORT. It reports that the PORT's pharmacoeconomist Shana Trice gave a statement on the Tricare health services program of the U.S. Military at the 2010 Federal Pharmacy Forum in Washington, D.C., that took place on March 12. Tricare health services stopped prescription of fentanyl transdermal patches in 2005. The change was done to prevent opioid side effects in the opiod-naive patients.


Related Articles

  • Efficacy, Safety and Pharmacokinetic Study of a Novel Fentanyl-Containing Matrix Transdermal Patch System in Japanese Patients with Cancer Pain. Miyazaki, Toyo; Hanaoka, Kazuo; Namiki, Akiyoshi; Ogawa, Setsuro; Kitajima, Toshimitsu; Hosokawa, Toyoshi; Ishida, Tomozo; Nogami, Shoji; Mashimo, Shigeto // Clinical Drug Investigation;2008, Vol. 28 Issue 5, p313 

    BACKGROUND AND: objectives: A novel transdermal matrix patch delivery system for fentanyl has been developed to deliver improved management of cancer pain compared with that obtained using current fentanyl reservoir patches. This study was carried out to assess the efficacy, safety and...

  • Clinical Pharmacokinetics of Transdermal Opioids. Grond, Stefan; Radbruch, Lukas; Lehmann, Klaus A. // Clinical Pharmacokinetics;2000, Vol. 38 Issue 1, p59 

    Transdermal delivery allows continuous systemic application of opioids through the intact skin. This review analyses the pharmacokinetic properties of transdermal opioid administration in the context of clinical experience, with a focus on fentanyl. A transdermal therapeutic system (TTS) for...

  • The delicate use of fentanyl patches.  // New Zealand Doctor;11/16/2011, p29 

    The article focuses on the use of fentanyl patches by general practitioners in palliative medicine. It explains the use of transdermal fentanyl in patients with renal dysfunction, have low tolerance to morphine and oral dosing is not applicable. It discusses the conditions when the opioid should...

  • Medication errors related to transdermal opioid patches: lessons from a regional incident reporting system. Lövborg, Henrik; Holmlund, Mikael; Hägg, Staffan // BMC Pharmacology & Toxicology;2014, Vol. 15 Issue 1, p1 

    Objective: A few cases of adverse reactions linked to erroneous use of transdermal opioid patches have been reported in the literature. The aim of this study was to describe and characterize medication errors (MEs) associated with use of transdermal fentanyl and buprenorphine. Methods: All...

  • Fentanyl Iontophoretic Transdermal System. Cada, Dennis J.; Levien, Terri; Baker, Danial E. // Hospital Pharmacy;Nov2006, Vol. 41 Issue 11, p1076 

    The article focuses on fentanyl iontophoretic transdermal system. It belongs to the therapeutic class of opioid analgesics and is similar to injectable patient-controlled analgesics. The drug can be used for the short-term management of acute postoperative pain in adult patients requiring opioid...

  • Transdermal Matrix Fentanyl Membrane Patch (Matrifen: In Severe Cancer-Related Chronic Pain. Hair, Philip I.; Keating, Gillian M.; McKeage, Kate // Drugs;2008, Vol. 68 Issue 14, p2001 

    â–´ The matrix fentanyl membrane patch is a new transdermal patch designed with a reduced drug load compared with established reservoir and matrix fentanyl patches. â–´ The drug is contained within a silicone matrix with a rate-controlling membrane designed to maintain constant serum...

  • Transdermal fentanyl: abuse by adolescents.  // WHO Drug Information;2005, Vol. 19 Issue 3, p207 

    The article focuses on the abuse of transdermal fentanyl by adolescents in Canada. Fentanyl transdermal system has been marketed in Canada since 1992 and is indicated for the management of chronic pain in patients requiring continuous opioid analgesia for pain that is not optimally managed with...

  • Jefferson-Led Study Shows Needle-Free Transdermal System as Effective as IV Pain Pump for Post-Surgical Pain While Giving Patients More Mobility, JAMA Reports.  // Ascribe Newswire: Medicine;3/24/2004, p43 

    A needle-free, self-contained fentanyl patient-controlled transdermal system is as effective for post-surgical pain management as the traditional intravenous pump (IV), while giving patients more mobility and freeing nurses to devote more time to patient care. The multi-center study conducted at...

  • DOD Launches 'Healthy Choices for Life' Pilot Program. Gilmore, Gerry J. // All Hands;Apr2005, Issue 1056, p5 

    Reports that the U.S. Department of Defense is launching a new preventive healthcare program called "Healthy Choices for Life," the department's senior medical adviser announced recently.


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics